1. The Promise That Fooled Everyone
Elizabeth Holmes arrived in the national conversation not with a bang, but with a whisper that sounded like the future. In 2013, The Wall Street Journal published a piece that wasn’t a science story or even a business story; it ran in the Opinion section, written by Pulitzer Prize–winning editorial board member Joseph Rago. The headline was almost poetic: “A Drop of Blood, an Instant Diagnosis.” The article painted Holmes as a visionary who wanted to put the power of medical testing directly into ordinary people’s hands. The appeal was immediate and emotional. Who wouldn’t want to prick a finger, send a single drop of blood to a lab, and receive instant answers about dozens of health conditions? It felt like magic, but it also felt like progress. Rago himself admitted he was impressed by the idea that individuals could finally have more control over their own health care. And then came the heavyweight endorsement: George Shultz, former secretary of state and a Theranos board member, told Rago that Holmes was the next Steve Jobs or Bill Gates. That comparison wasn’t just flattery; it was a cultural anchor. In the early 2010s, Silicon Valley was not just a place but a religion. The founders were prophets, and disruptive technology was the scripture. Holmes wore Steve Jobs’s uniform of black turtlenecks and spoke in a low, hypnotic voice. She had the confidence of someone who believed she was destined to rewrite the rules of medicine. It was intoxicating. And it was all built on a foundation that would later crumble into one of the most infamous frauds in modern business history. But in those early days, nobody wanted to ask the hard questions. Why? Because the story was too beautiful. A young woman, dropping out of Stanford, carrying the torch of innovation into a dusty, regulated industry, promising to make healthcare cheaper and easier—this wasn’t just a company. It was a narrative that Americans desperately wanted to believe. It was hope with a lab coat on.
2. The Electric Era of Tech and Theranos’ Place in It
By 2014, Holmes had become the youngest female billionaire in the world, at least on paper. Her company Theranos was valued at $9 billion. She was on every magazine cover, in every awards list, and being introduced at conferences with the kind of reverence usually reserved for rock stars. The mid-2010s felt electric. The iPhone had reshaped the world, Tesla was making electric cars cool, Airbnb was turning ordinary homes into hotels, and Twitter had arguably become the new public square. There was a sense that Silicon Valley could do no wrong, that any industry could be upended by a few brilliant people with laptops and venture capital. Theranos looked like the ultimate proof of this theory. If you could disrupt medicine, you could disrupt anything. WIRED, the magazine that had practically invented the cult of innovation, saw in Holmes a perfect protagonist. I was an editor there at the time, and Theranos-as-presented felt very WIRED. It validated a worldview that tech could be applied to every corner of human existence, even the vulnerable, physical world of health care. The magazine had long championed the idea of the “quantified self”—the notion that with the right data and technology, you could optimize your own body. Holmes was the living embodiment of that idea. She wasn’t a doctor, but she didn’t need to be; she was a technologist, and technologists were the new doctors. There was something almost spiritual about the faith being placed in her. People wanted to hand her their veins and say, “Tell me what’s wrong, and make it easy.” It didn’t hurt that Holmes was young, white, rich, and articulate in a way that made investors comfortable. She moved through the world not like a scientist but like a prophet. And the media, including WIRED, was more than happy to amplify her gospel. We didn’t run the tests. We didn’t verify the chemistry. We ran the story, because the story was what we were in the business of selling.
3. The Media Machine and the First Cracks
One of my colleagues at WIRED, editor Caitlin Roper, was drawn to Theranos and to Holmes in particular. The idea was to get close, to sit with her, to understand what was really going on behind the black turtleneck. The executive editor suggested Roper simply go talk to Holmes and see what was what. The result was a long-form Q&A with the catchy title “One Drop, Infinite Data: How Elizabeth Holmes Built a Better Blood Test.” It was published in the March 2014 issue of WIRED, because print magazines have never exactly been known for speed. By then, the rest of the media was catching on. Fortune put Holmes on its cover and lauded her as a genius. The New Yorker did a profile that was perhaps more flattering than it should have been in retrospect. In October 2015, Inc. magazine went all in, placing her on the cover with the label “the next Steve Jobs.” That issue was still warm on the newsstands when The Wall Street Journal dropped the bomb everyone had been too dazzled to look for. Reporter John Carreyrou’s article was headlined modestly: “Theranos Has Struggled with Blood Tests.” Uh-oh. The tone was calm, but the implications were devastating. A company that was supposed to be revolutionizing the diagnostic industry was having serious problems with the core product. The stories of former employees, leaked documents, and regulatory concerns began to stack up. Suddenly, the dazzling narrative started to look like a house of cards. The media that had helped build Holmes into a deity was now being forced to watch her fall. It was a lesson not just in fraud but in the dangers of a narrative-driven culture. We all wanted Theranos to be true. We wanted, maybe, to be told that the future could be better than our present. We wanted a hero. And when it turned out that the hero was a lie, we had to face the uncomfortable truth that we had played a role in making that lie possible.
4. The Collapse, the Grift, and the Human Cost
The truth, when it finally arrived, was not elegant. Theranos’s speedy and accurate blood tests were fake. The revolutionary new technology did not exist. The company was, at its heart, a grift. Walgreens, a major retail partner that had invested millions in rolling out Theranos testing centers, terminated its partnership. Patients had received lab results based on equipment and processes that were unproven, unvalidated, and in some cases, utterly fictional. The implications were terrifying. This wasn’t a startup that failed because the market wasn’t ready; it was a company that lied to regulators, doctors, and ordinary people about their own health. There were real consequences, not just financial but deeply personal. People had made medical decisions based on Theranos’s fraudulent results. Some had canceled insurance. Others had undergone unnecessary procedures. And through all of it, Holmes maintained a kind of strange, unsettling poise. She appeared at conferences and interviews with the same steely calm, insisting that everything was fine, that the press simply didn’t understand her technology. It was a performance that fooled the powerful for years, including brilliant men like George Shultz, and eventually would lead to her criminal conviction and a sentence of more than eleven years in prison. A new documentary film, released just as Holmes was preparing to begin her sentence, follows her in the weeks leading up to her incarceration. There is something haunting about watching the rise and fall in real time. She was not a cartoon villain but a human being—someone who made terrible choices, who surrounded herself with enablers, and who chose to protect an empire of lies rather than confess to a spectacular failure. The story of Theranos isn’t just about Elizabeth Holmes. It’s about every investor who didn’t ask the hard questions, every journalist who preferred the sexy story to the complicated truth, and every patient who believed in a promise that was never real.
5. The Soul-Searching of Those Who Told the Story
Get a bunch of old WIRED editors together these days, and it doesn’t take more than one drink before the conversation turns to guilt. We ask each other whether we enabled the worst parts of the tech world’s rise to power. Sometimes it seems like every weirdo with $100 billion and a government contract made his debut in our pages—whether they were building surveillance empires, lecturing the world about ethics while dodging taxes, or claiming that artificial intelligence was going to end civilization. We were the mouthpieces for an industry that often confused disruption with destruction and profitability with truth. So when Theranos and Holmes came back into the news, with the documentary and the prison sentence, the current administration at WIRED naturally wondered what we were thinking back then. The honest answer is that we were thinking what everyone else was thinking: she was a great story. She was a woman in a male-dominated field, she was brilliant, she was advancing the cause of innovation in healthcare, and she was going to change the world. It was exciting. It was hopeful. But that excitement carried a cost. When you tell stories about heroes, you sometimes stop checking whether the heroes are real. The entire culture of tech journalism in the 2010s was built on access, hype, and the assumption that founders were geniuses whose visions were worth celebrating. The people who questioned that assumption were often ignored, silenced, or mocked. We were all, to some degree, co-conspirators in the construction of a mythology that was never true. The lesson is not to stop believing in innovation or progress; the lesson is to bring skepticism, curiosity, and courage to the stories we tell. We owe it to the people who trust the media to separate what is real from what is merely a good narrative.
6. A Conversation with Caitlin Roper and the Meaning of It All
Caitlin Roper, who wrote that original WIRED Q&A with Holmes, has since moved on to an entirely different world as executive producer for scripted film and TV at The New York Times. But she still remembers what drew her to the Theranos story all those years ago. She was going through some medical issues of her own at the time and was having constant blood tests. She was tired of the needles, the wait, the anxiety, the opaque process. She was genuinely curious about what Theranos could do for people like her. She was interested in the idea of a female founder disrupting healthcare, in the possibility that there could be more transparency, more accessibility, and reduced costs. She wasn’t stupid. She wasn’t careless. She was hopeful. That, in the end, is the tragedy of Elizabeth Holmes. She weaponized hope. She took the very human desire to feel well, to know what was happening inside our bodies, and to have some control over a system that often feels impersonal and terrifying—and she turned it into a lie. But the lesson isn’t simply that hope is dangerous. It’s that hope must be paired with rigor. It must be tested. It must be protected from those who would exploit it. The Theranos story is a warning to all of us, journalists and patients, investors and dreamers. It reminds us that the most convincing people are not always the most honest, and that the promise of a better world is not a substitute for the difficult, unglamorous work of verifying whether that world can actually exist. As the documentary plays and the prison gates close, we are left not with certainty but with questions. Who enabled Holmes? We all did, in different ways. And from now on, we must ask: what else are we believing because we want it to be true? The story of Theranos is not just the story of a fraud. It is a mirror. And the most human thing we can do is look into it, wince, and determine to do better.
